BofA notes that Ascendis Pharma (ASND) shares are under pressure following a death reported in the FAERS database for Yorvipath, though the analyst also notes that company management express confidence that the event is unrelated to Yorvipath and cites other comorbidities as the likely cause. The firm, which awaits more details but remains confident in the risk/benefit of Yorvipath, has a Buy rating and $242 price target on Ascendis shares.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ASND:
- Ascendis Pharma price target raised to $242 from $230 at BofA
- Ascendis Pharma’s Promising Growth: Yorvipath Uptake and Anticipated TransCon CNP Approval Drive Buy Rating
- Ascendis Pharma initiated with a Strong Buy at Raymond James
- Ascendis Pharma Grants Employee Warrants to Boost Engagement
- Ascendis Pharma price target raised to $254 from $203 at Cantor Fitzgerald